TGFα and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells

Clinical Cancer Research

Volumn 20, Issue 24, 2014, Pages 6429-6438

  Hobor, Sebastijan ^a   Van Emburgh, Beth O ^a   Crowley, Emily ^a,b   Misale, Sandra ^a,c   Di Nicolantonio, Federica ^a,c   Bardelli, Alberto ^a,c  

^a UNIVERSITY OF TURIN   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; CETUXIMAB; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR ALPHA; CULTURE MEDIUM; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ARTICLE; CANCER CELL; CELL PROLIFERATION ASSAY; CELL PROTECTION; COCULTURE; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; DNA SEQUENCE; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PARACRINE SIGNALING; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CULTURE MEDIUM; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; ONCOGENE RAS; PHARMACOLOGY; SECRETION (PROCESS); TUMOR CELL LINE;

AMPHIREGULIN; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CULTURE MEDIA, CONDITIONED; DRUG RESISTANCE, NEOPLASM; GENES, RAS; HUMANS; MAP KINASE SIGNALING SYSTEM; MUTATION; PARACRINE COMMUNICATION; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 84908441752     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0774     Document Type: Article

References (37)

1. Yarom N, Jonker DJ. The role of the epidermal growth factor receptor in the mechanism and treatment of colorectal cancer. Discov Med 2011;11:95-105.
2. Bardelli A, Siena S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J Clin Oncol 2010;28: 1254-61.
3. Sartore-Bianchi A., Bencardino K, Di Nicolantonio F, Pozzi F, Funaioli C., Gambi V, et al. Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in meta-static colorectal cancer. Target Oncol 2010;5:19-28.
4. Patel GS, Karapetis CS. Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Manag Res 2013;5:387-400.
5. Blair BG, Bardelli A, Park BH. Somatic alterations as the basis for resistance to targeted therapies. J Pathol 2014;232:244-54.
6. Heinemann V, Douillard JY, Ducreux M, Peeters M. Targeted therapy in metastatic colorectal cancer - an example of personalised medicine in action. Cancer Treat Rev 2013;39:592-601.
7. Chong CR, Jänne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013;19:1389-400.
8. Diaz LA, Williams RT, Wu J, Kinde I., Hecht JR, Berlin J, et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012;486:537-40.
9. Misale S, Yaeger R, Hobor S., Scala E, Janakiraman M, Liska D., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012;486:532-6.
10. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
11. Donev IS, Wang W, Yamada T., Li Q, Takeuchi S, Matsumoto K., et al. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res 2011;17:2260-9.
12. Yano S, Takeuchi S, Nakaga Wat., Yamada T. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Cancer Sci 2012;103:1189-94.
13. Yao Z, Fenoglio S, Gao D.C., Camiolo M., Stiles B, Lindsted T, et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A 2010;107:15535-40.
14. Whitehead RH, Macrae FA, St John DJ, Ma J. A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. J Natl Cancer I 1985;74:759-65.
15. Misale S, Arena S, Lamba S., Siravegna G, Lallo A, Hobor S., et al. Blockadeof EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci Transl Med 2014;6:224ra26.
16. Liska D, Chen CT, Bachleitner-Hofmann T, Christensen J.G., Weiser MR. HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 2011;17:472-82.
17. Untawale S, Zorbas MA, Hodgson C.P., Coffey RJ, Gallick GE, North SM, et al. Transforming growth factor-alpha production and autoinduction in a colorectal carcinoma cell line (DiFi) with an amplified epidermal growth factor receptor gene. Cancer Res 1993;53:1630-6.
18. Olive M, Untawale S, Coffey R.J., Siciliano MJ, Wildrick DM, Fritsche H, et al. Characterization of the DiFi rectal carcinoma cell line derived from a familial adenomatous polyposis patient. In Vitro Cell Dev Biol 1993;29A:239-48.
19. Lu Y, Li X, Liang K., Luwor R, Siddik ZH, Mills G.B., et al. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 2007;67:8240-7.
20. Mutsaers AJ, Francia G, Man S., Lee CR, Ebos JM, Wu Y, et al. Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. Clin Cancer Res 2009;15: 2397-405.
21. Freeman DJ, McDorman K, Ogbagabriel S., Kozlosky C, Yang BB, Doshi S, et al. Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. Mol Cancer 2012;11:47.
22. Rodland KD, Bollinger N, Ippolito D., Opresko LK, Coffey RJ, Zangar R, et al. Multiple mechanisms are responsible for transactivation of the epidermal growth factor receptor in mammary epithelial cells. J Biol Chem 2008;283:31477-87.
23. Busser B, Sancey L, Brambilla E., Coll JL, Hurbin A. The multiple roles of amphiregulin in human cancer. Biochim Biophys Acta 2011;1816: 119-31.
24. Jacobs B, De Roock W, Piessevaux H, Van Oirbeek R, Biesmans B, De Schutter J, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009;27:5068-74.
25. Khambata-Ford S., Garrett CR, Meropol N.J., Basik M., Harbison CT, Wu S, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7.
26. Loupakis F, Cremolini C, Fioravanti A., Orlandi P, Salvatore L, Masi G., et al EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. Target Oncol 2013 Jul 3. [Epub ahead of print].
27. Minjgee M, Toulany M, Kehlbach R., Giehl K, Rodemann HP. K-RAS (V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs. Int J Radiat Oncol Biol Phys 2011;81:1506-14.
28. Toulany M, Baumann M, Rodemann HP. Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity. Mol Cancer Res 2007;5:863-72.
29. Castillo J, Erroba E, Perugorría MJ, Santamaría M, Lee D.C., Prieto J., et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 2006;66:6129-38.
30. Hurbin A, Dubrez L, Coll J.L., Favrot MC. Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines. J Biol Chem 2002; 277:49127-33.
31. Johnson GR, Saeki T, Gordon AW, Shoyab M, Salomon DS, Stromberg K. Autocrine action of amphiregulin in a colon carcinoma cell line and immunocytochemical localization of amphiregulin in human colon. J Cell Biol 1992;118:741-51.
32. Schulze A, Lehmann K, Jefferies H.B., McMahon M., Downward J. Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev 2001;15:981-94.
33. Gerlinger M, Rowan AJ, Horswell S, Larkin J., Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92.
34. S Datta R, Gutteridge A, Swanton C, Maley CC, Graham TA. Modelling the evolution of genetic instability during tumour progression. Evol Appl 2013;6:20-33.
35. Murugaesu N, Chew SK, Swanton C. Adapting clinical paradigms to the challenges of cancer clonal evolution. Am J Pathol 2013;182:1962-71.
36. Tougeron D, Lecomte T, Pages J.C., Villalva C., Collin C, Ferru A, et al. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann Oncol 2013; 24:1267-73.
37. Santini D, Vincenzi B, Addeo R., Garufi C, Masi G, Scartozzi M., et al Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann Oncol 2012;23:2313-8.